应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GENB Generate Biomedicines
休市中 09-04 16:00:00 EDT
16.39
+0.05
+0.31%
盘后
16.66
+0.27
+1.66%
19:54 EDT
最高
16.62
最低
15.98
成交量
72.53万
今开
16.39
昨收
16.34
日振幅
3.92%
总市值
21.01亿
流通市值
9.88亿
总股本
1.28亿
成交额
1,192万
换手率
1.20%
流通股本
6,029万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Generate Biomedicines:现有现金、现金等价物及有价证券足以支撑运营计划至2028年上半年
美股速递 · 08-06
Generate Biomedicines:现有现金、现金等价物及有价证券足以支撑运营计划至2028年上半年
Generate Biomedicines预计现有资金可支持运营至2028年上半年
美股速递 · 05-07
Generate Biomedicines预计现有资金可支持运营至2028年上半年
摩根士丹利首予Generate Biomedicines增持评级 目标价20美元
美股速递 · 03-24
摩根士丹利首予Generate Biomedicines增持评级 目标价20美元
Piper Sandler首予Generate Biomedicines增持评级 目标价24美元
美股速递 · 03-24
Piper Sandler首予Generate Biomedicines增持评级 目标价24美元
加载更多
公司概况
公司名称:
Generate Biomedicines
所属市场:
NASDAQ
上市日期:
--
主营业务:
Generate Biomedicines, Inc.于2018年8月根据特拉华州法律成立。作为一家临床阶段的生成生物学公司,该公司首创了名为Generate Platform的人工智能驱动的生物技术平台,该平台将计算模型与可扩展的生物硬件相结合,以设计和开发新型治疗性蛋白质。其最先进的候选药物GB-0895是一种计算工程抗TSLP单克隆抗体,目前正处于严重哮喘的关键3期试验中。该平台的能力已通过在2026年将另外两个肿瘤候选药物推向1期试验而得到进一步证明。
发行价格:
--
{"stockData":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":16.39,"timestamp":1788552000000,"preClose":16.34,"halted":0,"volume":725332,"hourTrading":{"tag":"盘后","latestPrice":16.6625,"preClose":16.39,"latestTime":"19:54 EDT","volume":4086,"amount":67095.7788,"timestamp":1788566048605,"change":0.2725,"changeRate":0.016626,"amplitude":0.018914},"delay":0,"changeRate":0.003059975520195882,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"休市中","change":0.05,"latestTime":"09-04 16:00:00 EDT","open":16.39,"high":16.62,"low":15.98,"amount":11918638.016032,"amplitude":0.039168,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":16.34,"preHourTrading":{"tag":"盘前","latestPrice":16.43,"preClose":16.34,"latestTime":"09:29 EDT","volume":1125,"amount":18533.750625,"timestamp":1788528599999,"change":0.09,"changeRate":0.005508,"amplitude":0.045288},"postHourTrading":{"tag":"盘后","latestPrice":16.6625,"preClose":16.39,"latestTime":"19:54 EDT","volume":4086,"amount":67095.7788,"timestamp":1788566048605,"change":0.2725,"changeRate":0.016626,"amplitude":0.018914},"volumeRatio":0.5323416494392342},"requestUrl":"/m/hq/s/GENB","defaultTab":"news","newsList":[{"id":"1196527286","title":"Generate Biomedicines:现有现金、现金等价物及有价证券足以支撑运营计划至2028年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1196527286","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196527286?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:13","pubTimestamp":1786014817,"startTime":"0","endTime":"0","summary":"Generate Biomedicines 宣布,公司当前持有的现金、现金等价物以及有价证券,已足够支持其现有运营计划,直至2028年上半年。这一资金储备状况,为公司未来的研发与业务拓展提供了坚实的财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176782309","title":"Generate Biomedicines预计现有资金可支持运营至2028年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1176782309","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176782309?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:21","pubTimestamp":1778149271,"startTime":"0","endTime":"0","summary":"Generate Biomedicines公司近日表示,其现有的现金、现金等价物及有价证券储备预计足以支撑公司日常运营持续至2028年上半年。这一资金规划为企业的长期发展战略提供了稳定的财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170560375","title":"摩根士丹利首予Generate Biomedicines增持评级 目标价20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170560375","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170560375?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:45","pubTimestamp":1774356311,"startTime":"0","endTime":"0","summary":"摩根士丹利宣布,首次覆盖生物医药公司Generate Biomedicines,并给予“增持”评级。该机构同时设定了20美元的目标股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184653688","title":"Piper Sandler首予Generate Biomedicines增持评级 目标价24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184653688","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184653688?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:44","pubTimestamp":1774338251,"startTime":"0","endTime":"0","summary":"Piper Sandler近日宣布,正式启动对生物医药公司Generate Biomedicines的研究覆盖,并给予其\"增持\"评级。该机构同时设定了24美元的目标股价,显示出对该公司未来增长潜力的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.generatebiomedicines.com","stockEarnings":[{"period":"1week","weight":0.0691},{"period":"1month","weight":0.1311},{"period":"3month","weight":0.2735},{"period":"6month","weight":0.4621},{"period":"1year","weight":0.0244},{"period":"ytd","weight":0.0244}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Generate Biomedicines, Inc.于2018年8月根据特拉华州法律成立。作为一家临床阶段的生成生物学公司,该公司首创了名为Generate Platform的人工智能驱动的生物技术平台,该平台将计算模型与可扩展的生物硬件相结合,以设计和开发新型治疗性蛋白质。其最先进的候选药物GB-0895是一种计算工程抗TSLP单克隆抗体,目前正处于严重哮喘的关键3期试验中。该平台的能力已通过在2026年将另外两个肿瘤候选药物推向1期试验而得到进一步证明。","exchange":"NASDAQ","name":"Generate Biomedicines","nameEN":"Generate Biomedicines"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Generate Biomedicines(GENB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Generate Biomedicines(GENB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Generate Biomedicines,GENB,Generate Biomedicines股票,Generate Biomedicines股票老虎,Generate Biomedicines股票老虎国际,Generate Biomedicines行情,Generate Biomedicines股票行情,Generate Biomedicines股价,Generate Biomedicines股市,Generate Biomedicines股票价格,Generate Biomedicines股票交易,Generate Biomedicines股票购买,Generate Biomedicines股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Generate Biomedicines(GENB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Generate Biomedicines(GENB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}